AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17548243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 16262574 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment with exercise protocol for 10 sessions over 2 weeks.
Number of subjects: 40
Study 16262574 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment with exercise protocol for 10 sessions over 2 weeks.
Number of subjects: 40
Study 11905448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental auscultation and traditional oral health care education
Number of subjects: 0
Study 11905448 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral health care education
Number of subjects: 0
Study 10069683 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (100 mg, p.o.)
Number of subjects: 6
Study 10069683 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (200 mg, p.o.)
Number of subjects: 6
Study 10069683 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg, p.o.)
Number of subjects: 6
Study 10069683 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (600 mg, p.o.)
Number of subjects: 6
Study 10069683 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (1,200 mg, p.o.)
Number of subjects: 6
Study 10069683 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol (control for xamoterol)
Number of subjects: 6
Study 10069683 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (after terbutaline treatment)
Number of subjects: 6
Study 7567313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten suspension (9 mg/kg once daily, max 400 mg)
Number of subjects: 1312
Study 1967592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fenoldopam mesylate, infused at a maximal dose increment of 0.2 microgram/kg/min, with a maximal infusion rate of 1.5 micrograms/kg/min.
Number of subjects: 0
Study 1967592 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside, infused at a maximal dose increment of 1 microgram/kg/min, with a maximal infusion rate of 8 micrograms/kg/min.
Number of subjects: 0
Study 1967592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (fenoldopam and nitroprusside)
Number of subjects: 0
Study 1967592 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 0
Study 1967592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 0
Study 7387812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (300 mg i.v.) during untreated condition (n=29)
Number of subjects: 41
Study 7387812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (300 mg i.v.) during treatment with propranolol (320 mg/day) (n=15)
Number of subjects: 41
Study 7387812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (300 mg i.v.) during treatment with propranolol plus atropine (0.04 mg/kg) (n=12)
Number of subjects: 41
Study 7387812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (300 mg i.v.) during propranolol (n=15)
Number of subjects: 41
Study 7387812 — intervention group
Group type: COMPARATOR
Intervention: Diazoxide (300 mg i.v.) without propranolol (n=15)
Number of subjects: 41
Study 7387812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (300 mg i.v.) during propranolol plus atropine (n=12)
Number of subjects: 41
Study 30586728 — intervention group
Group type: EXPERIMENTAL
Intervention: U-IR (LV unloading followed by immediate reperfusion)
Number of subjects: 50
Study 30586728 — intervention group
Group type: EXPERIMENTAL
Intervention: U-DR (LV unloading followed by delayed reperfusion after 30 minutes)
Number of subjects: 50
Study 30586728 — intervention group
Group type: COMPARATOR
Intervention: U-IR
Number of subjects: 50
Study 30586728 — intervention group
Group type: COMPARATOR
Intervention: U-DR
Number of subjects: 50
Study 28786854 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐ScEmo
Number of subjects: 61
Study 28786854 — intervention group
Group type: COMPARATOR
Intervention: Cogniplus
Number of subjects: 61
Study 25517261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patch (Durogesic® D-TRANS)
Number of subjects: 120
Study 25517261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23640130 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention imagery
Number of subjects: 104
Study 23640130 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal reduction imagery
Number of subjects: 104
Study 23640130 — intervention group
Group type: COMPARATOR
Intervention: Control imagery
Number of subjects: 104
Study 21177798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern (≤20% of total energy)
Number of subjects: 1580
Study 21177798 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 1580
Study 18581064 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein-2 (rhBMP-2)
Number of subjects: 11
Study 18581064 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone
Number of subjects: 11
Study 17714461 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning Ahead Together (PAT) document, a research advance directive (n=69)
Number of subjects: 149
Study 17714461 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=80)
Number of subjects: 149
Study 15121552 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 63
Study 15121552 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 63
Study 15121552 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to Hysterectomy
Number of subjects: 63
Study 11843850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg
Number of subjects: 44
Study 11843850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Number of subjects: 44
Study 11843850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9793698 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation
Number of subjects: 0
Study 9793698 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 7848930 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine sulfate (MSO4) via continuous infusion (initial bolus of 0.03 mg/kg, infusion of 0.01% morphine at 5 mL/hour, titrated from 0.2 to 1.0 mg/hour)
Number of subjects: 30
Study 7848930 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine sulfate (MSO4) via intermittent bolus (initial bolus of 0.07 mg/kg, followed by 2-5 mg on demand)
Number of subjects: 30
Study 3907037 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluid replacement (total volume of urine output + 30 ml/hr)
Number of subjects: 14
Study 3907037 — intervention group
Group type: COMPARATOR
Intervention: Low fluid replacement (constant 125 ml/hr)
Number of subjects: 14
Study 3907037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (High and Low fluid replacement)
Number of subjects: 14
Study 31397718 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessional home visiting intervention (n = 644)
Number of subjects: 1238
Study 31397718 — intervention group
Group type: COMPARATOR
Intervention: Standard care condition (n = 594)
Number of subjects: 1238
Study 31397718 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting intervention
Number of subjects: 1238
Study 31397718 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal breastfeeding for at least 3 months
Number of subjects: 1238
Study 31397718 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending a preschool crèche
Number of subjects: 1238
Study 29166769 — intervention group
Group type: EXPERIMENTAL
Intervention: NIL-CHF intervention (n = 301)
Number of subjects: 611
Study 29166769 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 310)
Number of subjects: 611
Study 27244204 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position technique
Number of subjects: 40
Study 27244204 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 40
Study 24684771 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT‐201 at 10 μg
Number of subjects: 151
Study 24684771 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT‐201 at 30 μg
Number of subjects: 151
Study 24684771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 24684771 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT‐201 at 10 μg (RCF subset)
Number of subjects: 151
Study 24684771 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT‐201 at 30 μg (RCF subset)
Number of subjects: 151
Study 24684771 — intervention group
Group type: COMPARATOR
Intervention: Placebo (RCF subset)
Number of subjects: 151
Study 22525444 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (nasal prongs, 1-2 L/min flow)
Number of subjects: 58
Study 22525444 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 58
Study 19837146 — intervention group
Group type: EXPERIMENTAL
Intervention: US(1) (2.72 W/cm(2))
Number of subjects: 10
Study 19837146 — intervention group
Group type: EXPERIMENTAL
Intervention: US(2) (3.50 W/cm(2))
Number of subjects: 10
Study 19837146 — intervention group
Group type: COMPARATOR
Intervention: No US
Number of subjects: 10
Study 19837146 — intervention group
Group type: EXPERIMENTAL
Intervention: US(1) and US(2)
Number of subjects: 10
Study 17663099 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-separated moxibustion at the navel
Number of subjects: 71
Study 17663099 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 71
Study 17663099 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (vitamin E capsules, 0.1 g twice daily)
Number of subjects: 71
Study 17470188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management program
Number of subjects: 147
Study 17470188 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing care
Number of subjects: 147
Study 14997748 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (Als)
Number of subjects: 0
Study 14997748 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 14997748 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant endocrine therapy
Number of subjects: 0
Study 14997748 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate markers in neo-adjuvant endocrine treatment
Number of subjects: 0
Study 11126208 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine/Ephedrine (CE) mixture (100 mg/10 mg for those <80 kg, 200 mg/20 mg for those >80 kg, taken three times daily)
Number of subjects: 32
Study 11126208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 32
Study 8694951 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal hernioplasty
Number of subjects: 87
Study 8694951 — intervention group
Group type: COMPARATOR
Intervention: Shouldice herniorrhaphy
Number of subjects: 87
Study 1571917 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose TBI (1000 cGy midplane, 800 cGy lungs) at HIGH dose rate (15 cGy/min)
Number of subjects: 157
Study 1571917 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose TBI (1000 cGy midplane, 800 cGy lungs) at LOW dose rate (6 cGy/min)
Number of subjects: 157
Study 1571917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated-dose TBI (1200 cGy midplane, 900 cGy lungs) at HIGH dose rate (6 cGy/min)
Number of subjects: 157
Study 1571917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated-dose TBI (1200 cGy midplane, 900 cGy lungs) at LOW dose rate (3 cGy/min)
Number of subjects: 157
Study 1571917 — intervention group
Group type: COMPARATOR
Intervention: Single-dose HIGH instantaneous dose rate TBI
Number of subjects: 157
Study 2989346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice with soluble pyrophosphates
Number of subjects: 0
Study 2989346 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice without soluble pyrophosphates (control)
Number of subjects: 0
Study 30647034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac output-guided fluid therapy with low-dose inotrope infusion
Number of subjects: 2502
Study 30647034 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2502
Study 26104031 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise park intervention group (EPIG)
Number of subjects: 120
Study 26104031 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 120
Study 24217699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroxoline (NTX) at 250 mg
Number of subjects: 6
Study 24217699 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim (TMP) at 200 mg
Number of subjects: 6
Study 24217699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroxoline (NTX) at 250 mg three times a day
Number of subjects: 6
Study 24217699 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-resistant Escherichia coli strain
Number of subjects: 6
Study 21849554 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-burst transcranial magnetic stimulation (TBS) targeting the posterior medial frontal cortex
Number of subjects: 0
Study 21849554 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 21849554 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation over another brain area
Number of subjects: 0
Study 19826023 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 1400
Study 19826023 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 1400
Study 17643389 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 95
Study 17643389 — intervention group
Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 95
Study 15006907 — intervention group
Group type: COMPARATOR
Intervention: Modified invitation letter
Number of subjects: 12240
Study 15006907 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter
Number of subjects: 12240
Study 15006907 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone reminder
Number of subjects: 12240
Study 15006907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of modified invitation, written reminder, and phone reminder
Number of subjects: 12240
Study 11306208 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal gel (1.0 mg estradiol daily)
Number of subjects: 24
Study 11306208 — intervention group
Group type: COMPARATOR
Intervention: Transdermal patch (50 microg/24 h)
Number of subjects: 24
Study 9336557 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of Panax ginseng C.A. Meyer (G115)
Number of subjects: 36
Study 9336557 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of Panax ginseng C.A. Meyer (G115)
Number of subjects: 36
Study 9336557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study 7953885 — intervention group
Group type: EXPERIMENTAL
Intervention: Employed women
Number of subjects: 121
Study 3680579 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute withdrawal from cigarette smoking
Number of subjects: 24
Study 3680579 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (smoking)
Number of subjects: 24
Study 29137964 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 30
Study 29137964 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 30
Study 26487588 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy initiation within 25 days post-surgery
Number of subjects: 1718
Study 26487588 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy initiation after 25 days post-surgery
Number of subjects: 1718
Study 24598777 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based treatment with email support by a urotherapist
Number of subjects: 21
Study 24598777 — intervention group
Group type: COMPARATOR
Intervention: Postal treatment program
Number of subjects: 21
Study 22265362 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 21
Study 22265362 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 21
Study 22265362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patient groups
Number of subjects: 21
Study 22265362 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy face condition
Number of subjects: 21
Study 20690401 — intervention group
Group type: EXPERIMENTAL
Intervention: WHOQOL‐BREF (quality of life measure)
Number of subjects: 70
Study 20690401 — intervention group
Group type: EXPERIMENTAL
Intervention: NEADL (functional measure)
Number of subjects: 70
Study 18395869 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast reporting by SMS (group A)
Number of subjects: 2782
Study 18395869 — intervention group
Group type: COMPARATOR
Intervention: Without mobile phone reporting (group B)
Number of subjects: 2782
Study 18395869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 2782
Study 16000353 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 138
Study 16000353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 12226603 — intervention group
Group type: EXPERIMENTAL
Intervention: LumaCure LED light-curing unit
Number of subjects: 100
Study 12226603 — intervention group
Group type: EXPERIMENTAL
Intervention: VersaLux LED light-curing unit
Number of subjects: 100
Study 12226603 — intervention group
Group type: COMPARATOR
Intervention: Optilux 501 halogen-based light-curing unit
Number of subjects: 100
Study 12226603 — intervention group
Group type: COMPARATOR
Intervention: ProLite halogen-based light-curing unit
Number of subjects: 100
Study 10220011 — intervention group
Group type: EXPERIMENTAL
Intervention: C-45T polymorphism in the Sp1 binding site of the CCK gene promoter region
Number of subjects: 322
Study 10220011 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 322
Study 10220011 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype groups among alcoholics
Number of subjects: 322
Study 7601635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ingestion
Number of subjects: 0
Study 7601635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2173011 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint alpha- and beta-adrenoreceptor pharmacological blocker
Number of subjects: 12
Study 2173011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 635456 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet swallows of 2.5, 5 and 10ml
Number of subjects: 8
Study 635456 — intervention group
Group type: COMPARATOR
Intervention: Dry swallows
Number of subjects: 8
Study 31318648 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal precursor cells as immunotherapy
Number of subjects: 0
Study 31318648 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 27808522 — intervention group
Group type: EXPERIMENTAL
Intervention: ProudToParent.org (PTP) program with a waiting period
Number of subjects: 182
Study 27808522 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PTP program or waiting period)
Number of subjects: 182
Study 27808522 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching full agreement in Title IV-D court
Number of subjects: 182
Study 27808522 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching agreements on specific issues (e.g., custody, child support)
Number of subjects: 182
Study 25781193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IUs daily for 3 months)
Number of subjects: 89
Study 25781193 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 89
Study 25781193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 89
Study 23273538 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide 5mg
Number of subjects: 167
Study 23273538 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide 10mg
Number of subjects: 167
Study 23273538 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 167
Study 20634675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 0
Study 20634675 — intervention group
Group type: COMPARATOR
Intervention: Pamindronate
Number of subjects: 0
Study 19481320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) vaccination (10 microg of vaccine every week for 8 weeks)
Number of subjects: 59
Study 19481320 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) vaccination (40 microg of vaccine at weeks 1 and 8)
Number of subjects: 59
Study 17095933 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I group (golfers with movement-related symptoms)
Number of subjects: 24
Study 17095933 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II group (golfers with anxiety-related symptoms)
Number of subjects: 24
Study 17095933 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure condition
Number of subjects: 24
Study 17095933 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure condition
Number of subjects: 24
Study 15109507 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clonazepam (1 mg tablet, sucked three times a day for 14 days)
Number of subjects: 48
Study 15109507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucked three times a day for 14 days)
Number of subjects: 48
Study 11295622 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dietary supplementation with selenium; dosage and duration not specified.
Number of subjects: 0
Study 11295622 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study 9085968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 15 mg/kg IV followed by two additional doses of 10 mg/kg each
Number of subjects: 75
Study 9085968 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 75
Study 9085968 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 75